J&J ($JNJ) pulls more children's drugs off store shelves

Johnson & Johnson ($JNJ) execs should write a blues song about recalls. The company has found more manufacturing problems at its now-closed-for-remodeling plant in Fort Washington, PA, so it's pulling about 4 million packages of children's Benadryl tablets and 800,000 bottles of junior Motrin caplets off store shelves and out of wholesale warehouses.

Packages of drugs that are already in consumers' hands aren't affected, however. The company says the products are safe for continued use, because they passed quality testing and haven't prompted any complaints about side effects.

Earlier this year, J&J's McNeil Consumer Healthcare unit recalled 34 million bottles of children's drugs made at the Fort Washington plant, and the FDA released a scathing inspection report about the facility's condition and procedures. The plant was shut down--and most of its work force laid off--so that it could be retooled to fix the problems. J&J said the latest recall stems from an internal manufacturing review prompted by the repeated quality problems.

Of course, the children's drug snafu isn't the only recall trouble J&J has faced recently; the company has withdrawn certain lots of other drugs, including adult versions of Benadryl and Tylenol, along with hip-replacement devices and contact lenses. In all, the company has pulled at least 15 different products, according to McNeil's recall website. The FDA and the Justice Department are investigating the recalls.

CEO Bill Weldon (photo) has revamped J&J's quality-control chart in an attempt to arrest the problems. And then there's the cleanup at the Fort Washington plant, which is expected to extend well into 2011. Plus, the company has stopped using wooden shipping pallets to prevent contamination by a wood preservative, which led to several of the adult-drug recalls. The company re-introduced its first children's Tylenol product last week.

- see the McNeil recall notices
- get more from the Wall Street Journal
- read the Reuters news
- check out the coverage from Bloomberg

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…